# Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

> **NCT01809392** · PHASE2,PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myelocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT01809392
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2013-12
- **Final completion:** 2015-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01809392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01809392, "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01809392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*